Markets

Sorrento (SRNE) Jumps: Stock Adds 11.0% in Session - Tale of the Tape

A generic image of a pen and on top of a chart.
Credit: Shutterstock photo

Sorrento Therapeutics, Inc. ( SRNE ) was a big mover last session with its shares rising just over 11% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This breaks the recent trend of the company, as the stock is now trading above the past one month's volatile price range of $9.19 to $10.37.

This biopharmaceutical company has witnessed no estimate revision in the last 30 days. The Zacks Consensus Estimate hasn't been in trend either. Yesterday's rally is encouraging though, so make sure to keep a close watch on this firm in the near future.

Sorrento currently has a Zacks Rank #3 (Hold) while its Earnings ESP is 0.00%.

Better-ranked Medical Product stocks include Enzymotec Ltd. ( ENZY ), Covidien plc ( COV ) and Stryker Corp. ( SYK ). While Enzymotec sports a Zacks Rank #1 (Strong Buy), Covidien and Stryker bear a Zacks Rank #2 (Buy).

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days . Click to get this free report >>

COVIDIEN PLC (COV): Free Stock Analysis Report

ENZYMOTEC LTD (ENZY): Free Stock Analysis Report

SORRENTO THERAP (SRNE): Get Free Report

STRYKER CORP (SYK): Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

SRNE SYK

Other Topics

Investing Stocks

Latest Markets Videos

Zacks

Zacks is the leading investment research firm focusing on stock research, analysis and recommendations. In 1978, our founder discovered the power of earnings estimate revisions to enable profitable investment decisions. Today, that discovery is still the heart of the Zacks Rank. A wealth of resources for individual investors is available at www.zacks.com.

Learn More